Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
|Slideshows|November 5, 2018
Treatment for Antipsychotic-Induced Tardive Dyskinesia: New Insights
Author(s)Brian Miller, MD, PhD, MPH
Tardive dyskinesia, an involuntary athetoid or choreiform movements, generally of the tongue, lower face and jaw, and extremities, is highly prevalent in patients with schizophrenia after long-term antipsychotic use. What about clozapine for TD?
Advertisement
Advertisement
Related to this article
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
2
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5